These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. New generation pharmacogenomic tools: a SNP linkage disequilibrium Map, validated SNP assay resource, and high-throughput instrumentation system for large-scale genetic studies. De La Vega FM; Dailey D; Ziegle J; Williams J; Madden D; Gilbert DA Biotechniques; 2002 Jun; Suppl():48-50, 52, 54. PubMed ID: 12083398 [TBL] [Abstract][Full Text] [Related]
4. The relative power of SNPs and haplotype as genetic markers for association tests. Bader JS Pharmacogenomics; 2001 Feb; 2(1):11-24. PubMed ID: 11258193 [TBL] [Abstract][Full Text] [Related]
5. The power of genome-wide association studies of complex disease genes: statistical limitations of indirect approaches using SNP markers. Ohashi J; Tokunaga K J Hum Genet; 2001; 46(8):478-82. PubMed ID: 11501946 [TBL] [Abstract][Full Text] [Related]
6. Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarrays. 22-24 January 2001, Zurich, Switzerland. Jain KK Pharmacogenomics; 2001 Feb; 2(1):73-7. PubMed ID: 11258200 [TBL] [Abstract][Full Text] [Related]
7. Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Bernig T; Chanock SJ Expert Rev Mol Diagn; 2006 May; 6(3):319-31. PubMed ID: 16706736 [TBL] [Abstract][Full Text] [Related]
8. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Nebert DW; Zhang G; Vesell ES Drug Metab Rev; 2008; 40(2):187-224. PubMed ID: 18464043 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular pharmacogenetics in the SNP era. Mooser V; Waterworth DM; Isenhour T; Middleton L J Thromb Haemost; 2003 Jul; 1(7):1398-402. PubMed ID: 12871273 [TBL] [Abstract][Full Text] [Related]
10. The limits of genome-wide methods for pharmacogenomic testing. Gamazon ER; Skol AD; Perera MA Pharmacogenet Genomics; 2012 Apr; 22(4):261-72. PubMed ID: 22344246 [TBL] [Abstract][Full Text] [Related]
11. High throughput genotyping technologies for pharmacogenomics. Brennan MD Am J Pharmacogenomics; 2001; 1(4):295-302. PubMed ID: 12083961 [TBL] [Abstract][Full Text] [Related]
12. Mapping the new frontier: complex genetic disorders. Mayeux R J Clin Invest; 2005 Jun; 115(6):1404-7. PubMed ID: 15931374 [TBL] [Abstract][Full Text] [Related]
13. Single nucleotide polymorphism and its dynamics for pharmacogenomics. Katara P Interdiscip Sci; 2014 Jun; 6(2):85-92. PubMed ID: 25172446 [TBL] [Abstract][Full Text] [Related]
14. [Analysis and application of SNP and haplotype in the human genome]. Li J; Pan YC; Li YX; Shi TL Yi Chuan Xue Bao; 2005 Aug; 32(8):879-89. PubMed ID: 16231744 [TBL] [Abstract][Full Text] [Related]
15. Tag SNP selection for association studies. Stram DO Genet Epidemiol; 2004 Dec; 27(4):365-74. PubMed ID: 15372618 [TBL] [Abstract][Full Text] [Related]
16. Selecting single-nucleotide polymorphisms for association studies with SNPbrowser software. De La Vega FM Methods Mol Biol; 2007; 376():177-93. PubMed ID: 17984546 [TBL] [Abstract][Full Text] [Related]
17. What will whole genome searches for susceptibility genes for common complex disease offer to clinical practice? Lango H; Weedon MN J Intern Med; 2008 Jan; 263(1):16-27. PubMed ID: 18088250 [TBL] [Abstract][Full Text] [Related]
18. Common deletions and SNPs are in linkage disequilibrium in the human genome. Hinds DA; Kloek AP; Jen M; Chen X; Frazer KA Nat Genet; 2006 Jan; 38(1):82-5. PubMed ID: 16327809 [TBL] [Abstract][Full Text] [Related]
19. Mapping genes for common diseases: the case for genetic (LD) maps. Collins A; Lau W; De La Vega FM Hum Hered; 2004; 58(1):2-9. PubMed ID: 15604559 [TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics and genotyping: on the trail of SNPs. Melton L Nature; 2003 Apr; 422(6934):917, 919, 921, 923. PubMed ID: 12712209 [No Abstract] [Full Text] [Related] [Next] [New Search]